SLC34A2/NPT2B recombinant proteins and antibodies

Solute Carrier Family 34 Member 2 (SLC34A2), also known as NPT2B, is a sodium-dependent phosphate transporter primarily expressed in tissues such as the lungs, kidneys, and small intestine. It plays a crucial role in the regulation of cellular phosphate balance, particularly in maintaining the proper concentration and absorption of phosphate. SLC34A2 is involved in several physiological processes, including bone metabolism, kidney function, and immune system regulation.

In cancer research, SLC34A2 has garnered significant attention. The target is highly expressed in certain types of lung cancer, particularly non-small cell lung cancer (NSCLC). Studies have shown that SLC34A2 may contribute to tumor cell proliferation, migration, and drug resistance, and its abnormal expression is closely associated with tumor progression. As such, SLC34A2 has emerged as a promising target, especially for targeted therapies in malignancies such as lung cancer.

Currently, ongoing drug development targeting SLC34A2 mainly focuses on antibody therapies and small molecule inhibitors. Monoclonal antibodies targeting this receptor have already entered clinical trials. Additionally, several biopharmaceutical companies are exploring small molecule drugs aimed at inhibiting SLC34A2, with the goal of reducing tumor cell proliferation and metastasis. Globally, multiple pharmaceutical companies have begun to invest in research related to the SLC34A2 target. For example, Genentech in the United States and Novartis in Switzerland are both advancing SLC34A2-targeted drug development. Genentech is developing an antibody-drug conjugate (ADC) targeting SLC34A2 and is currently in the preclinical stage of testing its efficacy in lung cancer and other tumors. Novartis is also developing a small molecule inhibitor, which will be administered orally to target and inhibit SLC34A2 activity in tumor cells. As research into the SLC34A2 target progresses, it is expected that a range of new treatment options will emerge, particularly in lung cancer and other diseases related to phosphate metabolism.

To assist in the development of drugs targeting SLC34A2, DIMA BIOTECH can now provide full-length SLC34A2 recombinant membrane protein developed by its nanodisc membrane protein platform. SLC34A2 nanodisc is an optimal solution for screening small molecules targeting SLC34A2 with its natural structure. Furthermore, DIMA BIOTECH has also prepared a SLC34A2 single B cell seed library, from which lead antibody molecules can be obtained in as fast as 28 days.